Urovant Sciences GmbH et al v. Intas Pharmaceuticals Limited et al
Delaware District Court | |
Judge: | Gregory B Williams |
Case #: | 1:25-cv-00373 |
Nature of Suit | 835 Property Rights - Patent – Abbreviated New Drug Application |
Cause | 35:1 Patent Infringement |
Case Filed: | Mar 26, 2025 |
Last checked: Friday Mar 28, 2025 1:08 AM EDT |
Defendant
Accord Healthcare Inc.
|
|
Defendant
Intas Pharmaceuticals Limited
|
|
Plaintiff
Sumitomo Pharma America, Inc.
|
Represented By
|
Plaintiff
Urovant Sciences GmbH
|
Represented By
|
Docket last updated: 1 hours ago |
Wednesday, April 02, 2025 | ||
utility
Case Assigned/Reassigned
Wed 04/02 11:41 AM
Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. Associated Cases: 1:25-cv-00372-GBW, 1:25-cv-00373-GBW (rjb) |
||
Thursday, March 27, 2025 | ||
6 | 6
![]() Summons Issued as to Accord Healthcare Inc. on 3/27/2025; Intas Pharmaceuticals Limited on 3/27/2025.(oam) |
|
Att: 1
![]() |
||
Wednesday, March 26, 2025 | ||
5 | 5
![]() Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sumitomo Pharma Switzerland GmbH, Other Affiliate Sumitomo Chemical Co., Ltd., Other Affiliate Sumitomo Pharma Co., Ltd. for Urovant Sciences GmbH; Corporate Parent Sumitomo Pharma Co., Ltd., Other Affiliate Sumitomo Chemical Co., Ltd. for Sumitomo Pharma America, Inc. filed by Sumitomo Pharma America, Inc., Urovant Sciences GmbH. (oam) |
|
4 | 4
![]() Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 12,102,638 B2. (oam) |
|
2 | 2
![]() Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (oam) |
|
1 | 1
![]() COMPLAINT for PATENT INFRINGEMENT filed against Accord Healthcare Inc., Intas Pharmaceuticals Limited ( Filing fee $ 405, receipt number ADEDC-4646846.) - filed by Sumitomo Pharma America, Inc., Urovant Sciences GmbH.(oam) |
|
Att: 1
![]() |
||
Att: 2
![]() |
||
Thursday, March 06, 2025 | ||
3 | 3
![]() Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 02/11/2025. Date of Expiration of Patent: 03/22/2040. Thirty Month Stay Deadline: 6/23/2028. (oam) |